window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 13, 2025

  • News
  • About Us
Contact Us

Lepodisiran

  • Clinical Trials

    Eli Lilly’s Lepodisiran cuts heart disease risk factor by 94% in Phase 2 trial

    April 24, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Cereno taps global CRO for next big step in pulmonary hypertension drug trial
    Categories: Clinical Trials, Drug Development, Rare Diseases
  • Eleva doses first volunteers with new therapy targeting rare kidney disease
    Categories: Biologics & Biosimilars, Clinical Trials, Drug Development, Rare Diseases
  • First-in-class cell therapy for rare mitochondrial disorder gains FDA fast track
    Categories: Cell & Gene Therapy, Clinical Trials, Rare Diseases, Regulatory Affairs
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top